by The global medical foods market size was valued at USD 20.2 billion in 2020, and is predicted to be worth around USD 32.5 billion by 2030, registering a CAGR of 5.1% during the forecast period 2022 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39141
Table of Contents
Medical Foods Market Growth Factors
Increasing incidences of chronic diseases, the rising geriatric population, and the growing burden of malnutrition are the major factors responsible for the substantial growth of the market over the years. For instance, according to a WHO report, about 149 million children under 5 were stunted and 38.9 million were obese or overweight due to undernutrition in 2020. The emerging focus of the policymakers to manage chronic disorders and nutritional deficiency is also anticipated to drive the adoption of medical foods over the years.
The growing prevalence of communicable and non-communicable diseases and increasing effort for the dietary management of those diseases are anticipated to propel the market growth over the forecast years. For instance, as per the research data published by the University of Liege, it has been estimated that in Europe, the sarcopenia population will increase to 12.9% by 2045 from 11.1% in 2016.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 32.5 billion by 2030 |
| Growth Rate | CAGR of 5.1% From 2022 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Route of administration, Product, Application, Sales Channel |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | AT&T; Samsung Electronics Co.; Allscripts Healthcare Solutions; Apple, Inc.; Orange; mQure; Qualcomm Technologies, Inc.; SoftServe; Google, Inc, Airstrip Technologies, Inc.; Telefonica S.A.; Vodafone Group |
By Product Analysis
The powder segment accounted for the largest revenue share of over 35.0% in 2021 owing to the high commercial availability of medical foods in the form of powder. In addition, increasing preference and ease in consumption by the pediatric and geriatric patients suffering from different chronic diseases are fueling the segment growth.
The liquid segment is anticipated to grow at the fastest rate during the forecast period owing to the rising adoption of liquid formulations in the pediatric and geriatric population, where the intake of solid formulations is limited or impossible and in case of clinically diagnosed dysphagia or when oral physiology is limited.
By Application Analysis
Chemotherapy-induced diarrhea accounted for the largest revenue share of over 15.0% in 2021. Diarrheal episodes interfere with the chemotherapy process and dosage pattern. Therefore, the rising need for adopting medical foods in dietary management is expected to boost the segment growth.
Because of loss of absorptive surfaces and potential mucosal damage due to chemotherapy-related diarrhea, patients should ingest specific easy-to-digest medical food, which is expected to fuel the segment growth over the forecast years.
Diabetic neuropathy is anticipated to be the fastest-growing segment over the forecast period owing to the growing prevalence of diabetes and a rise in the number of patients that are at risk of developing some level of neuropathy.
The growing number of patients suffering from diabetic neuropathy and increasing prescription by medical professionals for medical food consumption to manage the disease are the major factors propelling the segment growth. The growing prevalence of diabetic neuropathy all over the globe is further supporting the growth of the segment.
By Sales Channel Analysis
The institutional sales channel, which includes hospitals, home care settings, and disability facilities, accounted for the largest revenue share of over 40.0% in 2021. The growing number of patient visits to the hospitals and other healthcare facilities for the diagnosis and treatment of several chronic and dietary disorders is driving the segment.
The increasing preference among the patients to consult a doctor in the hospitals for their chronic disease management will drive the segment. Moreover, the growing number of private and public healthcare institutions and the increasing chronic disease patient population across the globe will support the segment growth.
The online sales segment is anticipated to expand at the fastest rate over the forecast period. Preference for the online purchase of medical foods is rising owing to the convenience offered by this sales channel. Although medical foods are mainly consumed under medical surveillance, these are intended for long-term nutrition management, which is resulting in surging sales through e-commerce.
By Regional Analysis
North America held the largest revenue share of over 30.0%. The presence of international companies such as Abbott Laboratories and Mead Johnson & Company and the high revenue generation of these companies are driving the market.
The Asia Pacific region is anticipated to be the fastest-growing regional market over the forecast period owing to the increasing rate of cancer and diabetic patients, along with several government initiatives in the healthcare segment.
Johnson & Johnson Pte. Ltd. company, Asia Pacific hosts about 50% of new cancer cases in the world each year. Further, this report stated that the death due to cancer is estimated to increase by 36% in the Asia Pacific region by 203o, which, in turn, is expected to propel the growth of the market in this region over the coming years.
Read also @ Healthcare Software As A Service Market to Reach US$ 60.7 Bn by 2030
Major Key Players Covered in The Medical Foods Market Report include
- Nestle
- Danone
- Abbott
- Mead Johnson & Company, LLC
- Fresenius Kabi
- Targeted Medical Pharma, Inc.
- Primus Pharmaceuticals, Inc.
- Medtrition, Inc.
Medical Foods Market Segmentation
- By Route of Administration
- Oral
- Enteral
- By Product
- Pills
- Powder
- Liquid
- Others
- By Application
- Chronic Kidney Disease
- Minimal Hepatic Encephalopathy
- Chemotherapy Induced Diarrhea
- Pathogen Related Infections
- Diabetic Neuropathy
- ADHD
- Depression
- Alzheimer’s Disease
- Nutritional Deficiency
- Orphan diseases
- Phenylketonuria
- Tyrosinemia
- Eosinophilic esophagitis
- FPIES
- MSUD
- Homocystinuria
- Others
- Wound Healing
- Chronic Diarrhea
- Constipation Relief
- Protein Booster
- Dysphagia
- Pain Management
- Parkinson’s Disease
- Epilepsy
- Other Cancer related treatments
- Severe protein allergy
- Other
- By Sales Channel
- Online Sales
- Institutional Sales
- Retail Sales
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Singapore
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Application Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Medical Foods Market, By Route of Administration
7.1. Medical Foods Market, by Route of Administration, 2021-2030
7.1.1. Oral
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Enteral
7.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Medical Foods Market, By Product
8.1. Medical Foods Market, by Product, 2021-2030
8.1.1. Pills
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Powder
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Liquid
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Medical Foods Market, By Application
9.1. Medical Foods Market, by Application, 2021-2030
9.1.1. Chronic Kidney Disease
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Minimal Hepatic Encephalopathy
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Chemotherapy Induced Diarrhea
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Pathogen Related Infections
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Diabetic Neuropathy
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. ADHD
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Depression
9.1.7.1. Market Revenue and Forecast (2019-2030)
9.1.8. Alzheimer’s Disease
9.1.8.1. Market Revenue and Forecast (2019-2030)
9.1.9. Nutritional Deficiency
9.1.9.1. Market Revenue and Forecast (2019-2030)
9.1.10. Orphan diseases
9.1.10.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Medical Foods Market, By Sales Channel
10.1. Medical Foods Market, by Sales Channel, 2021-2030
10.1.1. Online Sales
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Institutional Sales
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Retail Sales
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Medical Foods Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.1.2. Market Revenue and Forecast, by Product (2019-2030)
11.1.3. Market Revenue and Forecast, by Application (2019-2030)
11.1.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.1.6.2. Market Revenue and Forecast, by Product (2019-2030)
11.1.6.3. Market Revenue and Forecast, by Application (2019-2030)
11.1.6.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.2.2. Market Revenue and Forecast, by Product (2019-2030)
11.2.3. Market Revenue and Forecast, by Application (2019-2030)
11.2.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.2.8.2. Market Revenue and Forecast, by Product (2019-2030)
11.2.8.3. Market Revenue and Forecast, by Application (2019-2030)
11.2.8.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.3.2. Market Revenue and Forecast, by Product (2019-2030)
11.3.3. Market Revenue and Forecast, by Application (2019-2030)
11.3.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.3.8.2. Market Revenue and Forecast, by Product (2019-2030)
11.3.8.3. Market Revenue and Forecast, by Application (2019-2030)
11.3.8.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.4.2. Market Revenue and Forecast, by Product (2019-2030)
11.4.3. Market Revenue and Forecast, by Application (2019-2030)
11.4.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.4.8.2. Market Revenue and Forecast, by Product (2019-2030)
11.4.8.3. Market Revenue and Forecast, by Application (2019-2030)
11.4.8.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.5.2. Market Revenue and Forecast, by Product (2019-2030)
11.5.3. Market Revenue and Forecast, by Application (2019-2030)
11.5.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Route of Administration (2019-2030)
11.5.6.2. Market Revenue and Forecast, by Product (2019-2030)
11.5.6.3. Market Revenue and Forecast, by Application (2019-2030)
11.5.6.4. Market Revenue and Forecast, by Sales Channel (2019-2030)
Chapter 12. Company Profiles
12.1. Nestle
12.1.1. Company Overview
12.1.2. Route of Administration Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Danone
12.2.1. Company Overview
12.2.2. Route of Administration Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott
12.3.1. Company Overview
12.3.2. Route of Administration Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Mead Johnson & Company, LLC
12.4.1. Company Overview
12.4.2. Route of Administration Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Fresenius Kabi
12.5.1. Company Overview
12.5.2. Route of Administration Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Targeted Medical Pharma, Inc.
12.6.1. Company Overview
12.6.2. Route of Administration Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Primus Pharmaceuticals, Inc.
12.7.1. Company Overview
12.7.2. Route of Administration Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Medtrition, Inc.
12.8.1. Company Overview
12.8.2. Route of Administration Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39141
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
